Skip to main content
PTIX
OTC Life Sciences

Cash Runway Narrows to Q3 2026 as Going Concern Doubts Deepen for Protagenic Therapeutics

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.35
Mkt Cap
$633.573K
52W Low
$0.128
52W High
$6.2
52W Position info
173% above low
Off High info
94% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

PTIX has more than doubled off its 52-week low of $0.128 on light trading volume (0.4× avg).

Summary

Protagenic Therapeutics' Q1 FY2027 10-Q shows cash of $565,985, enough to fund operations only until about the end of Q3 2026, with substantial doubt about its ability to continue as a going concern.


Key Events · Earnings and Guidance · PTIX

  • Cash Runway Only Through Q3 2026

    Cash of $565,985 as of June 30, 2026, funds operations only until approximately the end of Q3 2026, with no committed sources of additional capital.

  • Going Concern Doubt Reaffirmed

    Management states substantial doubt about the company's ability to continue as a going concern within one year after the financial statements are issued.

  • Working Capital Deficit

    Working capital deficit of $362,743 as of June 30, 2026, versus working capital of $511,107 at March 31, 2026.

  • Unsolicited Partnership Inquiry

    Company received an unsolicited inquiry regarding a potential partnership from an established company with expertise in neurobiology, and is broadening outreach to additional candidates.


Analysis · PTIX · Life Sciences

The 10-Q confirms a deteriorating cash position of $565,985, which funds operations only until approximately the end of Q3 2026. Management states substantial doubt about the company's ability to continue as a going concern within one year. Strategic alternatives are being explored, including a potential partnership for its lead program, but no financing is committed. This is a critical liquidity update for a micro-cap biotech already delisted from Nasdaq.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 48.1% of the 1752 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PTIX was trading at $0.35 on OTC in the Life Sciences sector, with a market capitalization of approximately $633.6K. The 52-week trading range was $0.13 to $6.20. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PTIX - Latest Insights

PTIX
Nov 11, 2026, 8:30 AM EST
Source: ACCESS Newswire
Importance Score:
7
Price at Filing: $0.49345
Real-time Price: $0.49345 info
Change: $0 (0%) info
Market Cap: $893.247K info
PTIX
Aug 20, 2026, 11:26 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.400
Real-time Price: $0.49345 info
Change: +$0.09345 (+23%) info
Market Cap: $893.247K info
PTIX
Aug 14, 2026, 3:19 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $0.360
Real-time Price: $0.49345 info
Change: +$0.13345 (+37%) info
Market Cap: $893.247K info
PTIX
Apr 06, 2026, 7:13 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.530
Real-time Price: $0.49345 info
Change: -$0.03655 (-7%) info
Market Cap: $893.247K info
PTIX
Mar 09, 2026, 7:51 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $0.4211
Real-time Price: $0.49345 info
Change: +$0.07235 (+17%) info
Market Cap: $893.247K info